The presence of cytotoxic T cells and evidence for brachyury tumour antigen-mediated immune activity, along with high expression of PD-L1, were compatible with the notion that the observed responses to nivolumab may have been driven by disinhibition of this brachyury-specific T cell clone and potentially other tumour-reactive T cells. Here, TBX1 is linked to neoplasm.